@article{73dee79255fb4166a61807769f5708d1,
title = "AN UPDATE OF A PHASE II STUDY OF PACLITAXEL IN ADVANCED OR RECURRENT SQUAMOUS CELL CANCER OF THE CERVIX",
author = "Kudelka, \{Andrzej P.\} and Rodger Winn and Edwards, \{Creighton L.\} and G. Downey and Harvey Greenberg and Dakhil, \{S. R.\} and Freedman, \{Ralph S.\} and Salvatore LoCoco and J. Umbreit and Delmore, \{James E.\} and Susan Arbuck and Evelyne Loyer and Patsy Gacrama and Rebecca Fueger and Kavanagh, \{John J.\}",
note = "Thirty-two evaluable patients with squamous cell cancer of the cervix were treated with i.v. paclitaxel 250 mg/m 2 over 3 h every 21 days. They received standard premedications and granulocyte colony stimulating factor (G-CSF) support (5 μg/kg/day). Median (range) age was 49 (29-81) years and performance status Zubrod was 1 (0-2).",
year = "1997",
month = aug,
day = "1",
doi = "10.1097/00001813-199708000-00002",
language = "American English",
volume = "8",
journal = "Anti-Cancer Drugs",
number = "7",
}